Research programme: diagnostic and therapeutic products - Dyax/EPIX Pharmaceuticals
Latest Information Update: 27 Mar 2008
At a glance
- Originator Dyax; EPIX Pharmaceuticals
- Class Imaging agents; Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Nov 2004 Preclinical trials in Thrombosis in USA (unspecified route)